



Parabolic Drugs Limited

Registered Office: S.C.O. 99 -100, Top Floor, Sector - 17 B, Chandigarh

Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi

Website: www.parabolicdrugs.com, Ph.: 91-172-3914646/47, Fax: 91-172-3914645

Unaudited Financial Results for the Quarter/Half Year ended 30th September, 2010

(Rs. In Crores)

Particulars	Quarter ended 30/09/2010	Quarter ended 30/09/2009	Half Year ended 30/09/2010	Half Year ended 30/09/2009	Accounting Year ended 31/03/2010
	Unaudited	Audited	Unaudited	Audited	Audited
1. Income :					
a) Gross Sales	161.43	138.88	301.58	251.59	559.00
Less : Excise Duty	(14.57)	(10.97)	(27.24)	(19.24)	(45.12)
Net Sales/Income from Operations	146.86	127.91	274.34	232.35	513.88
(b) Other Operating Income	0.59	0.93	0.91	1.07	4.87
Total	147.45	128.84	275.25	233.42	518.75
2. Expenditure :					
a) (Increase)/Decrease in stock in trade and work in progress	(46.97)	(27.37)	(63.16)	(36.23)	(52.06)
b) Consumption of Raw Materials	151.03	114.86	257.49	200.93	419.91
c) Employees Cost	4.00	4.57	7.46	7.01	13.90
d) Depreciation & Amortisations	4.36	2.24	8.71	4.91	10.07
e) Other Expenditure	9.69	11.57	18.02	19.58	44.67
Total	122.11	105.87	228.52	196.20	436.49
3. Profit from Operations before Other Income, Interest & Exceptional Items	25.34	22.97	46.73	37.22	82.26
4. Other Income	-	-	-	-	-
5. Profit before Interest & Exceptional Items (3 + 4)	25.34	22.97	46.73	37.22	82.26
6. Interest	6.54	13.70	14.43	19.17	38.22
7. Profit after interest but before Exceptional Items (5-6)	18.80	9.27	32.30	18.05	44.04
8. Exceptional Items	-	-	-	-	-
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	18.80	9.27	32.30	18.05	44.04
10. Tax expenses	4.51	3.85	7.48	4.90	9.84
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	14.29	5.42	24.82	13.15	34.20
12. Extra Ordinary Items	-	-	-	-	-
13. Net Profit (+)/ Loss(-) for the period (11-12)	14.29	5.42	24.82	13.15	34.20
14. Paid-up equity share capital (Face Value of Rs. 10/- each)	61.89	10.75	61.89	10.75	37.25
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	121.37
16. Earnings Per Share (EPS)					
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.31	5.04	4.93	12.23	17.91
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.31	4.41	4.93	10.70	17.91
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.31	5.04	4.93	12.23	17.91
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.31	4.41	4.93	10.70	17.91



17. Public Shareholding :					
- Number of Shares	38346994	2998960	38346994	2998960	13706029
- Percentage of Shareholding	61.96	27.90	61.96	27.90	36.79
18. Promoters and Promoter Group Shareholding (non-encumbered) :					
- Number of shares	23545020	7750540	23545020	7750540	23545020
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	38.04	72.10	38.04	72.10	63.21

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 8th November, 2010. The above results are subject to Limited Review by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
2. During the period, the Company has : Filed three Drug Master Files (DMFs), one each in US, Canada and European Union; successfully executed bulk orders for exports to Europe; successfully cleared the customer Audits by three US MNCs and three of the top ten Indian MNCs and Japanese Innovator partner.
3. There were no investor complaints pending at the beginning of the quarter. Twelve complaints received from the shareholders during the quarter have been disposed off. No investor complaint was pending at the end of the quarter.

4. Statement of Assets & Liabilities :

(Rs. In crores)

Particulars	As at 30/09/2010 (Unaudited)	As at 30/09/2009 (Audited)
Shareholders Funds :		
Share Capital	61.89	35.75
Reserves & Surplus	306.35	97.79
Loan Funds	373.42	343.22
Deferred Tax Liability	8.67	6.37
Total	750.33	483.13
Fixed Assets	210.82	140.00
Investments	1.99	1.98
Current Assets, Loans & Advances :		
Inventories	298.48	220.16
Sundry Debtors	246.25	156.43
Cash & Bank Balances	32.68	25.03
Loan & Advances	44.31	36.33
Less : Current Liabilities & Provisions	150.64	119.09
Miscellaneous Expenditure (to the extent not written off or adjusted)	66.44	22.29
Total	750.33	483.13

5. The above results are on stand alone basis.
6. There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
7. Figures of the previous year have been rearranged/regrouped wherever necessary.

Place :Chandigarh
Date :8th November, 2010

For Parabolic Drugs Ltd.

